210 related articles for article (PubMed ID: 38571939)
21. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans.
Tortorici MA; Addetia A; Seo AJ; Brown J; Sprouse K; Logue J; Clark E; Franko N; Chu H; Veesler D
Immunity; 2024 Apr; 57(4):904-911.e4. PubMed ID: 38490197
[TBL] [Abstract][Full Text] [Related]
22. SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
Roa CC; de Los Reyes MRA; Plennevaux E; Smolenov I; Hu B; Gao F; Ilagan H; Ambrosino D; Siber G; Clemens R; Han HH
Hum Vaccin Immunother; 2024 Dec; 20(1):2301632. PubMed ID: 38206168
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates.
Routhu NK; Stampfer SD; Lai L; Akhtar A; Tong X; Yuan D; Chicz TM; McNamara RP; Jakkala K; Davis-Gardner ME; St Pierre EL; Smith B; Green KM; Golden N; Picou B; Jean SM; Wood J; Cohen J; Moore IN; Patel N; Guebre-Xabier M; Smith G; Glenn G; Kozlowski PA; Alter G; Ahmed R; Suthar MS; Amara RR
Sci Immunol; 2023 Oct; 8(88):eadg7015. PubMed ID: 37191508
[TBL] [Abstract][Full Text] [Related]
24. Functional antibody responses targeting the Spike protein of SARS-CoV-2 Omicron XBB.1.5 in elderly nursing home residents following Wuhan-Hu-1-based mRNA booster vaccination.
Sánchez-Simarro Á; Fernández-Soto D; Grau B; Albert E; Giménez E; Avilés-Alía AI; Gozalbo-Rovira R; Rusu L; Olea B; Geller R; Reyburn HT; Navarro D
Sci Rep; 2024 May; 14(1):11896. PubMed ID: 38789475
[TBL] [Abstract][Full Text] [Related]
25. Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors.
Lu BN; Zhu KL; Cui XM; Yao L; Wang XJ; Wang GL; Duan LJ; Qian A; Ma MJ
Clin Immunol; 2022 Nov; 244():109103. PubMed ID: 36049602
[TBL] [Abstract][Full Text] [Related]
26. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
[TBL] [Abstract][Full Text] [Related]
28. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
29. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
[TBL] [Abstract][Full Text] [Related]
31. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
32. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
[TBL] [Abstract][Full Text] [Related]
33. Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.
Laquintana V; Mottini C; Marchesi F; Marcozzi B; Terrenato I; Sperandio E; de Latouliere L; Carrieri F; Pimpinelli F; Pontone M; Pellini R; Campo F; Conti L; Accetta C; Mandoj C; Petrone F; Di Bella O; Vujovic B; Morrone A; Compagnone M; Principato E; Pinto E; Papa E; Falcucci P; La Malfa A; Pallocca M; De Marco F; Piaggio G; Ciliberto G; Mengarelli A; di Martino S
Front Immunol; 2023; 14():1221587. PubMed ID: 38343436
[TBL] [Abstract][Full Text] [Related]
34. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
[TBL] [Abstract][Full Text] [Related]
35. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
[TBL] [Abstract][Full Text] [Related]
36. Tracking the immune response profiles elicited by the BNT162b2 vaccine in COVID-19 unexperienced and experienced individuals.
Galeota E; Bevilacqua V; Gobbini A; Gruarin P; Bombaci M; Pesce E; Favalli A; Lombardi A; Vincenti F; Ongaro J; Fabbris T; Curti S; Martinovic M; Toccafondi M; Lorenzo M; Critelli A; Clemente F; Crosti M; Sarnicola ML; Martinelli M; La Sala L; Espadas A; Donnici L; Borghi MO; De Feo T; De Francesco R; Prati D; Meroni PL; Notarbartolo S; Geginat J; Gori A; Bandera A; Abrignani S; Grifantini R
Clin Immunol; 2024 Apr; 261():110164. PubMed ID: 38417765
[TBL] [Abstract][Full Text] [Related]
37. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
39. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
[TBL] [Abstract][Full Text] [Related]
40. Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.
Kalnin KV; Plitnik T; Kishko M; Huang D; Raillard A; Piolat J; Anosova NG; Tibbitts T; DiNapoli J; Karve S; Goldman R; Gopani H; Dias A; Tran K; Zacharia M; Gu X; Boeglin L; Abysalh J; Vargas J; Beaulieu A; Shah M; Jeannotte T; Gillis K; Chivukula S; Swearingen R; Landolfi V; Fu TM; DeRosa F; Casimiro D
Vaccine; 2022 Feb; 40(9):1289-1298. PubMed ID: 35101265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
